Bitcoin has fallen about 29% over the past month, sparking debate over whether the downturn is nearing a bottom or has further to runBitcoin has fallen about 29% over the past month, sparking debate over whether the downturn is nearing a bottom or has further to run

History says 365 days to bottom — but this Bitcoin cycle may be different

2026/02/18 02:54
3 min di lettura
Per feedback o dubbi su questo contenuto, contattateci all'indirizzo crypto.news@mexc.com.

Bitcoin slid more than 2% to $67,000 on Tuesday, reflecting broader risk aversion across markets as Wall Street reopened after the Presidents’ Day holiday.

Summary
  • Tech and crypto remain under pressure, while defensives are mixed, with selective strength emerging in activist-driven and travel names.
  • Bitcoin has fallen about 29% over the past month, sparking debate over whether the downturn is nearing a bottom or has further to run.
  • “I believe that bitcoin has already capitulated with that big move from 100k-> 60k,” one analyst says.

Crypto weakness coincided with renewed pressure on technology and software shares, where investors continued to grapple with the potential for AI-driven disruption. The Nasdaq-100 underperformed, slipping 0.3%, while the iShares Expanded Tech-Software Sector ETF dropped more than 2.7% in midday New York trading. The software-focused fund has now declined in 11 of the past 15 sessions, pushing its year-to-date losses to nearly 25%.

Broader equity indices were largely flat, masking sharp divergences beneath the surface. Financial stocks rebounded after weeks of weakness, while consumer staples lagged.

Travel Tickers

Travel-linked shares stood out as a pocket of strength. Norwegian Cruise Line Holdings surged 11% after Elliott Investment Management disclosed a stake exceeding 10% and signaled plans to push for strategic changes following the cruise operator’s prolonged underperformance.

Peers rallied in sympathy, with Carnival Corp. rising about 4% and Royal Caribbean Group gaining 3%.

In travel and leisure, Airbnb Inc. added 3.7%, extending momentum from last week’s earnings report. Southwest Airlines Co. jumped more than 6% following a wave of analyst upgrades from Susquehanna and UBS.

But what about Bitcoin?

The top cryptocurrency has fallen about 29% over the past month, sparking debate over whether the downturn is nearing a bottom or has further to run.

Trader Altcoin Sherpa pointed to past cycles for comparison, noting that both the 2017–2018 and 2021–2022 bear markets saw steep 75–85% drawdowns and took roughly a year from all-time high to final bottom. Each cycle ended with a sharp capitulation event — including the 2018 plunge from $6,000 to $3,000 and the 2022 crash tied to FTX — followed by several months of accumulation.

However, Sherpa argues the current cycle may differ. The 2024–2025 rally was slower and more consolidation-heavy than prior vertical surges, and structural factors such as spot ETFs, reduced speculative excess, stronger support in the $50,000–$70,000 range, and already-flushed altcoin froth could shorten the bear market timeline, potentially avoiding a full 365-day decline.

“I believe that bitcoin has already capitulated with that big move from 100k-> 60k,” Sherpa says. “I believe we are now in the ACCUMULATION phase of the cycle. Accumulation can last anywhere from a few weeks to several months.”

See the full post via the link below.

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: gli articoli ripubblicati su questo sito provengono da piattaforme pubbliche e sono forniti esclusivamente a scopo informativo. Non riflettono necessariamente le opinioni di MEXC. Tutti i diritti rimangono agli autori originali. Se ritieni che un contenuto violi i diritti di terze parti, contatta crypto.news@mexc.com per la rimozione. MEXC non fornisce alcuna garanzia in merito all'accuratezza, completezza o tempestività del contenuto e non è responsabile per eventuali azioni intraprese sulla base delle informazioni fornite. Il contenuto non costituisce consulenza finanziaria, legale o professionale di altro tipo, né deve essere considerato una raccomandazione o un'approvazione da parte di MEXC.

Potrebbe anche piacerti

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Condividi
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Condividi
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Condividi
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage